Compare IDT & KARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IDT | KARD |
|---|---|---|
| Founded | 1990 | 2023 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | |
| Sector | Telecommunications | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | 1996 | 2026 |
| Metric | IDT | KARD |
|---|---|---|
| Price | $77.30 | $13.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $41.00 |
| AVG Volume (30 Days) | 128.6K | ★ 437.9K |
| Earning Date | 12-03-2026 | 11-12-2026 |
| Dividend Yield | ★ 0.36% | N/A |
| EPS Growth | ★ 14.95 | N/A |
| EPS | ★ 3.46 | N/A |
| Revenue | ★ $1,231,495,000.00 | N/A |
| Revenue This Year | $2.39 | N/A |
| Revenue Next Year | $0.75 | $50.00 |
| P/E Ratio | $22.47 | ★ N/A |
| Revenue Growth | ★ 2.13 | N/A |
| 52 Week Low | $46.48 | $12.23 |
| 52 Week High | $84.56 | $27.00 |
| Indicator | IDT | KARD |
|---|---|---|
| Relative Strength Index (RSI) | 38.45 | 42.66 |
| Support Level | $51.16 | $12.28 |
| Resistance Level | $84.48 | $16.26 |
| Average True Range (ATR) | 2.14 | 1.26 |
| MACD | -0.86 | -0.08 |
| Stochastic Oscillator | 14.00 | 14.03 |
IDT Corp is a multinational holding company. It operates in the telecommunications and payment industries. It has four reportable business segments, Fintech, National Retail Solutions; net2phone and Traditional Communications, The Fintech segment is comprised of National Retail Solutions (NRS), an operator of a nationwide point of sale (POS) network providing payment processing, digital advertising, transaction data, and ancillary services, and BOSS Money, a provider of international money remittance and related value/payment transfer services. The net2phone segment provides unified cloud communications and telephony services to business customers.
Kardigan Inc is a clinical-stage therapeutics company focused on developing medicines for cardiovascular diseases. Its activities include the research and development of targeted therapies for cardiovascular conditions for which no approved treatments currently exist. The company's clinical-stage programs include Danicamtiv, Ataciguat, and Tonlamarsen, which are being developed for cardiovascular disease indications. The company operates and manages its business as a single operating and reportable segment, focused on the discovery and development of novel therapeutic products to treat cardiovascular disease.